ES2164703T3 - Metodo para el tratamiento de la enfermedad neoplasica utilizando la tiazofurina y la ribavirina. - Google Patents

Metodo para el tratamiento de la enfermedad neoplasica utilizando la tiazofurina y la ribavirina.

Info

Publication number
ES2164703T3
ES2164703T3 ES94916011T ES94916011T ES2164703T3 ES 2164703 T3 ES2164703 T3 ES 2164703T3 ES 94916011 T ES94916011 T ES 94916011T ES 94916011 T ES94916011 T ES 94916011T ES 2164703 T3 ES2164703 T3 ES 2164703T3
Authority
ES
Spain
Prior art keywords
tiazofurin
treatment
ribavirin
imp
remission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916011T
Other languages
English (en)
Inventor
George Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Application granted granted Critical
Publication of ES2164703T3 publication Critical patent/ES2164703T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL TRATAMIENTO DE ENFERMEDAD NEOPLASTICA EN ANIMALES DE SANGRE CALIENTE USANDO LA ADMINISTRACION SECUENCIAL DE TIAZOFURINO Y RIBAVIRINA. EL TIAZOFURINO SE ADMINISTRA PRIMERO EN UNA DOSIS GRANDE CON EL FIN DE FACILITAR UNA DECRECIMIENTO SOSTENIDO EN LA ACTIVIDAD IMO DH. ESTAS GANANCIAS SE CONSOLIDAN POR A ADMINISTRACION CONTINUA DE TIAZOFURINA HASTA QUE LOS NIVELES HEMATOLOGICOS SE ESTABILICEN Y SE ALCANCE LA REMISION. UNA VEZ QUE EL PACIENTE ESTA EN FASE DE REMISION, SE ADMINISTRA RIBAVIRINA EN DOSIS DE REDUCCION ESTABILIZADA HASTA QUE DOSIS MINIMA QUE RETIENE EL EFECTO BENEFICIOSO DEL TIAZOFURINA SEA REALIZADA. LA ACTIVIDAD IMP DH, LA CONCENTRACION GTP, Y LOS DATOS HEMATOLOGICOS ESTA CONTINUAMENTE MONITORIZADO A TRAVES DE TODO EL TRATAMIENTO Y LAS DOSIS AJUSTADAS.
ES94916011T 1993-05-18 1994-05-05 Metodo para el tratamiento de la enfermedad neoplasica utilizando la tiazofurina y la ribavirina. Expired - Lifetime ES2164703T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/065,348 US5405837A (en) 1993-05-18 1993-05-18 Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin

Publications (1)

Publication Number Publication Date
ES2164703T3 true ES2164703T3 (es) 2002-03-01

Family

ID=22062092

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916011T Expired - Lifetime ES2164703T3 (es) 1993-05-18 1994-05-05 Metodo para el tratamiento de la enfermedad neoplasica utilizando la tiazofurina y la ribavirina.

Country Status (14)

Country Link
US (1) US5405837A (es)
EP (1) EP0707479B1 (es)
JP (1) JP2951407B2 (es)
KR (1) KR100310121B1 (es)
AT (1) ATE208201T1 (es)
AU (1) AU679531B2 (es)
BR (1) BR9406534A (es)
CA (1) CA2161970C (es)
DE (1) DE69428995T2 (es)
ES (1) ES2164703T3 (es)
HK (1) HK1011614A1 (es)
NZ (1) NZ266359A (es)
RU (1) RU2149004C1 (es)
WO (1) WO1994026281A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
BR0213861A (pt) * 2001-11-02 2004-12-21 Sandoz Ag Processo para a preparação de composições de ribavirina de carga elevada, de dissolução rápida
AU2003261354A1 (en) * 2002-08-02 2004-02-23 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CA2572223C (en) * 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
KR101162710B1 (ko) * 2009-01-23 2012-07-05 (주) 비엔씨바이오팜 도라지 추출물 또는 도라지 사포닌 화합물을 함유하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4680285A (en) * 1980-12-15 1987-07-14 Viratek, Inc. Treatment of malignant tumors with 2-(β-D-ribofuranosylthiazole-4-carboxamide related compounds
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment

Also Published As

Publication number Publication date
EP0707479A4 (en) 1998-04-15
DE69428995D1 (de) 2001-12-13
AU679531B2 (en) 1997-07-03
US5405837A (en) 1995-04-11
WO1994026281A1 (en) 1994-11-24
JPH08510450A (ja) 1996-11-05
CA2161970A1 (en) 1994-11-24
RU2149004C1 (ru) 2000-05-20
KR960702313A (ko) 1996-04-27
NZ266359A (en) 1997-07-27
KR100310121B1 (ko) 2001-12-28
CA2161970C (en) 2005-06-21
EP0707479B1 (en) 2001-11-07
EP0707479A1 (en) 1996-04-24
BR9406534A (pt) 1996-01-02
JP2951407B2 (ja) 1999-09-20
AU6782794A (en) 1994-12-12
HK1011614A1 (en) 1999-07-16
DE69428995T2 (de) 2002-06-06
ATE208201T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
IS2630B (is) Meðferð á fráhvarfseinkennum
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ES2067939T3 (es) Sistema de distribucion de un medicamento iontoforetico con un perfil de reparto de dos etapas.
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
FR2512670B1 (fr) Capsules contenant le principe actif d'un allergene et procede pour leur preparation
BR9912356A (pt) Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato
FI3749308T3 (fi) Potilaiden, joilla on klassinen fabryn tauti, hoito migalastaatilla
ES2164703T3 (es) Metodo para el tratamiento de la enfermedad neoplasica utilizando la tiazofurina y la ribavirina.
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
RU95122466A (ru) Способ лечения неопластического заболевания с помощью тиазофурина и рибавирина
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
ES2052475T1 (es) Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14.
Rossetti Single-shot vs conventional therapy with amikacin for treatment of uncomplicated urinary tract infections: a multicenter study
KR900017599A (ko) 종양 치료용 약학 조성물
RU93021361A (ru) Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом
RU2021123887A (ru) Схемы введения тиреоидного гормона Т4
何金森 et al. COMPARATIVE ANALYSIS OF THERAPEUTIC EFFECTS OF ACUPUNCTURE IN THE TREATMENT OF HYPERTHYROIDISM
KR900002779A (ko) 종양치료용 약학 조성물
RO96749A2 (ro) Medicament vasoactiv
Goldner et al. The Effect of Nicotinic Acid on the Blood Cholesterol Level in Man
RU2000111645A (ru) Способ лечения геморрагической лихорадки с почечным синдромом
Shell et al. Effects of Medication on Respiration Pattern of Tranquilized White Mice
RU98111518A (ru) Способ лечения хронического полимиозита
RU94045317A (ru) Способ лечения вилюйского энцефаломиелита
RU96104613A (ru) Способ лечения больных эндокринной офтальмопатией

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707479

Country of ref document: ES